# Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

> **NCT07491211** · — · ACTIVE_NOT_RECRUITING · sponsor: **Fudan University** · enrollment: 300 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
- Osimertinib
- Stereotactic Radiation

## Interventions

- **DRUG:** Osimertinib
- **RADIATION:** intracranial stereotactic radiotherapy

## Key facts

- **NCT ID:** NCT07491211
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-19
- **Primary completion:** 2025-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07491211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07491211, "Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07491211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*